NASDAQ: VTRS · Specialty & Generic Drug Manufacturers
Viatris (VTRS) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Viatris (VTRS) at $26.77 a share. The stock last closed at $20.28, which puts the model's fair value 32.0% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 18 Nov 2026. Viatris Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $25.88 to $26.77 (+3.4%). The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move.
What the model makes of itThe price of $20.28 is 32.0% below it: Undervalued, on a medium evidence grade.
What's nextNext report on 25 Feb 2027. Options prices imply a move of about 11% either way over the next month. On the model's Scorecard Leaders list since 17 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give VTRS?
The calibrated range for VTRS over 63 trading days is $17.94 to $23.07. It sits around the last close, and its width comes from the volatility that VTRS's own options imply (37% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $17.78 to $38.13. In 69% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets.
Faircurve's model put the fair value of Viatris at $26.77 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $25.88, so the fair value moved +3.4%. The model's reason, in its own words: the stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The calibrated range over 63 trading days is $18.35 to $22.91. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium, based on how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
Viatris scores 36 out of 100 on the model's overall quality score, a composite of six quality factors scored against comparable companies. Three factors stand out most. Profitability scores 0, with ROIC at -0.3% against a peer median of 11.4%. Stability scores 4, with EBITDA margin downside volatility over five years at 10.5 pts against a peer median of 7.6 pts. Earnings quality scores 85. The model compares Viatris with Zoetis Inc. (ZTS) and Alkermes plc (ALKS), each of which has its own fair value on the site.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does VTRS report earnings, and how has the stock reacted?
Viatris's next earnings report is scheduled for 25 Feb 2027. Companies can move their dates.
Options prices on 18 Nov 2026 imply a move of about 8.4% in either direction through the nearest expiry, about 29 days out. That is the size the market is pricing, not a direction. VTRS's 30 day implied volatility works out to about 10.7% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across VTRS's last 8 reports, ignoring direction, was 7.0%.
What the options market has priced for a month's move in VTRS
How does VTRS score on business quality?
Viatris's overall quality score is 36 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 0 | -0.3%ROIC | 11.4% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 85 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 39 | -3.0%Revenue growth, trailing | 4.3% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 73 | 1.6%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 38 | 4.13xNet debt / EBITDA | 4.02x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 4 | 10.5 ptsEBITDA margin downside volatility, 5y | 7.6 pts |
How does VTRS compare with similar companies?
The companies in specialty & generic drug manufacturers closest to Viatris in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ZTS Zoetis Inc. | $85.57 | $83.75 | -2.1% | Fairly valued |
| ELAN Elanco Animal Health Incorporated | $26.70 | $25.34 | -5.1% | Low evidence grade |
| ALKS Alkermes plc | $46.85 | $46.51 | -0.7% | Fairly valued |
| AMRX Amneal Pharmaceuticals, Inc. | $21.88 | $19.34 | -11.6% | Low evidence grade |
| LNTH Lantheus Holdings, Inc. | $102.00 | $100.64 | -1.3% | Data under review |
| SUPN Supernus, Inc. | $28.96 | $29.86 | +3.1% | Low evidence grade |
| ANIP ANI Pharmaceuticals, Inc. | $71.47 | $76.30 | +6.8% | Low evidence grade |
| PAHC Phibro Animal Health Corporation | $35.57 | $36.25 | +1.9% | Low evidence grade |
What the comparable companies' multiples alone would give for VTRS, the peer-implied price, is $44.18 a share on this run. The fair value weighs that against the company's own multiple.
All specialty & generic drug manufacturer stocks ranked by gap to fair value
Viatris at a glance
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets.
- Market value
- $23.9B
- Sector
- Healthcare
- Industry
- Specialty & Generic Drug Manufacturers
- Revenue expected, next twelve months
- $15.3B
- Consensus revenue growth, next fiscal year
- +3.5%
- Analysts with estimates
- 6
- Beta to the US market
- 0.58
- First valued by Faircurve
- 1 May 2026
At the close of 18 Nov 2026, 60.4% of the 1,083 graded US stocks the model covers traded below the model's fair value. VTRS was among them.
How the fair value is worked out: the model prices Viatris on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for VTRS was $25.88. As of 14 Nov 2026 it is $26.77, a change of +3.4%. The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Viatris's valuation
Is Viatris stock undervalued or overvalued?
On Faircurve's model, VTRS reads as Undervalued as of 14 Nov 2026. The model's fair value is $26.77 a share against a last close of $20.28, a gap of +32.0%.
What is VTRS's fair value?
$26.77 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $17.78 to $38.13.
What price range does the model give VTRS?
$17.94 to $23.07 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Viatris report earnings next?
The next report is scheduled for 25 Feb 2027. Companies can move their dates.
How much has VTRS moved on past earnings reports?
Across its last 8 reports the median two session move was 7.0%, ignoring direction. The largest was -17.9% around the report of 27 Feb 2025.
How confident is the model in this valuation?
The model's evidence grade for VTRS is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on VTRS
The model has an idea open on VTRS under Scorecard Leaders since 17 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on VTRS with their outcomes. A free account is enough.